News & Updates

Male sex tied to better outcomes in early ACPA-negative rheumatoid arthritis
Male sex tied to better outcomes in early ACPA-negative rheumatoid arthritis
10 Sep 2022

Men with anticitrullinated peptide antibody (ACPA)-negative early rheumatoid arthritis (RA) tend to have favourable clinical outcomes than their female counterparts, a study has shown. However, such benefit is not seen in those with ACPA-positive early RA.

Male sex tied to better outcomes in early ACPA-negative rheumatoid arthritis
10 Sep 2022
Dactylitis predicts more severe joint damage, higher disease activity in axPsA
Dactylitis predicts more severe joint damage, higher disease activity in axPsA
10 Sep 2022

The presence of dactylitis in patients with axial psoriatic arthritis (axPsA) may result in higher disease activity and more severe joint damage compared to those without, reports a study.

Dactylitis predicts more severe joint damage, higher disease activity in axPsA
10 Sep 2022
Thrombocytopaenia, platelet dysfunction common in Parkinson’s disease
Thrombocytopaenia, platelet dysfunction common in Parkinson’s disease
10 Sep 2022
COVID-19 lockdown weakens metabolism in people with glucose intolerance
COVID-19 lockdown weakens metabolism in people with glucose intolerance
10 Sep 2022

In Japan, the declaration of a state of emergency in response to the COVID-19 pandemic led to negative metabolic consequences in people with glucose intolerance, such as lowered skeletal muscle and increased body weight and body fat, a recent study has found.

COVID-19 lockdown weakens metabolism in people with glucose intolerance
10 Sep 2022
Trifluridine/tipiracil add-on to bevacizumab safe, effective for mCRC
Trifluridine/tipiracil add-on to bevacizumab safe, effective for mCRC
09 Sep 2022

In patients with metastatic colorectal cancer (mCRC), using trifluridine/tipiracil with bevacizumab is a safe and effective treatment for refractory disease, a recent study has found.

Trifluridine/tipiracil add-on to bevacizumab safe, effective for mCRC
09 Sep 2022
Low-dose methotrexate-related melanoma risk considered negligible
Low-dose methotrexate-related melanoma risk considered negligible
09 Sep 2022